These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. In vitro and in vivo activity of melflufen (J1)in lymphoma. Delforoush M; Strese S; Wickström M; Larsson R; Enblad G; Gullbo J BMC Cancer; 2016 Apr; 16():263. PubMed ID: 27044263 [TBL] [Abstract][Full Text] [Related]
5. Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma. Morabito F; Tripepi G; Martino EA; Vigna E; Mendicino F; Morabito L; Todoerti K; Al-Janazreh H; D'Arrigo G; Canale FA; Cutrona G; Neri A; Martino M; Gentile M Drug Des Devel Ther; 2021; 15():2969-2978. PubMed ID: 34262262 [TBL] [Abstract][Full Text] [Related]
6. A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells. Ray A; Ravillah D; Das DS; Song Y; Nordström E; Gullbo J; Richardson PG; Chauhan D; Anderson KC Br J Haematol; 2016 Aug; 174(3):397-409. PubMed ID: 27098276 [TBL] [Abstract][Full Text] [Related]
7. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. Richardson PG; Bringhen S; Voorhees P; Plesner T; Mellqvist UH; Reeves B; Paba-Prada C; Zubair H; Byrne C; Chauhan D; Anderson K; Nordström E; Harmenberg J; Palumbo A; Sonneveld P Lancet Haematol; 2020 May; 7(5):e395-e407. PubMed ID: 32213344 [TBL] [Abstract][Full Text] [Related]